Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress.

“We continue to transform cancer care with Kisqali, building on its established profile in the metastatic setting and now helping a wide range of people as they strive to stay cancer-free ...

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...

The green light means that Kisqali is now available “in multiple indications through the NHS which, coupled with the recent ASCO data demonstrating increased survival for pre-menopausal women ...

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. NBC News' Kathy Park speaks to a ...

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment ...

The FDA expanded approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The decision will free up access to the medication for tens of ...

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...

Kisqali is a prescription drug used with other medications to treat certain kinds of breast cancer. Kisqali can cause side effects that range from mild to serious, such as fatigue, hair loss, and ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset. For patients with hormone receptor ...

Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali ® (ribociclib) in combination with an aromatase inhibitor (AI ...